Clover Biopharmaceuticals FY2025 loss narrows 77.3% to RMB205 million; revenue drops 90.9% to RMB3.5 million

Reuters03-26
Clover Biopharmaceuticals FY2025 loss narrows 77.3% to RMB205 million; revenue drops 90.9% to RMB3.5 million
  • Clover published an annual results announcement reporting revenue of RMB3.5 million, down 90.88%, mainly due to the termination of AdimFlu-S $(QIS)$ commercial activities in mainland China with the remaining revenue reflecting a return-rate true-up on prior-period sales.
  • Loss for the year narrowed to RMB205.1 million, down 77.3%, primarily because a full provision of COVID-19 vaccine related raw materials was recorded in the prior year.
  • Cash and bank balances fell to RMB271.4 million, down 51.23%, mainly due to bank-loan repayment, continued R&D investment and daily operations.
  • Research and development expenses were RMB182.3 million, down 0.57%, as Clover streamlined operations and prioritized respiratory vaccine candidates.
  • Pipeline updates included positive Phase 1 data for RSV combination candidates SCB-1022 and SCB-1033 and interim Phase 1 results for RSV re-vaccination candidate SCB-1019, with full results expected in the first half of 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clover Biopharmaceuticals Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260326-12067909), on March 25, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment